Amgen, AstraZeneca Highlight Brodalumab Data to be Presented at EADV
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV) in Istanbul, Oct. 2-6, 2013.
"The Phase 2 data demonstrate that the primary and secondary end points were met, including many patients achieving and maintaining total skin clearance with continued brodalumab therapy," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We look forward to further investigating brodalumab for patients with moderate to severe psoriasis."
Dr. Bahija Jallal, executive vice president, MedImmune added, "We're very encouraged by these results and the initiation of our Phase 3 program."
In Oct. 2012, the companies announced the start of the Phase 3 program in moderate to severe psoriasis for brodalumab. The program consists of three Phase 3 studies evaluating treatment with brodalumab compared with ustekinumab and/or placebo.
Abstracts will be presented during the poster session on Friday, Oct. 4, 2013.
Abstracts of Interest Include:
Maintenance of Clinical